RDCC’s Response to 21st Century Cures Act and Cures 2.0 Request for Information

Washington, DC – The Rare Disease Company Coalition (RDCC) has submitted a response to the 21st Century Cures and Cures 2.0 Request for Information, offering recommendations for policy improvements to facilitate the discovery, development, and delivery of treatments for people living with a rare disease.

RDCC applauds the longstanding leadership of Rep. DeGette and Rep. Bucshon in developing and advancing policy solutions on behalf of the 1 in 10 Americans living with a rare disease. 21st Century Cures and Cures 2.0 yielded notable progress in advancing the development and availability of treatments for rare diseases, but there is a critical need for further action to address the unmet needs associated with rare disease. In particular, the RDCC recommends that the 21st Century Cures initiative ensures:

• Consistent and appropriate use of regulatory flexibilities in rare disease drug development and review; and
• Timely access to rare disease treatments and diagnoses.

By supporting these initiatives, Congress can help create an environment where effective treatments for rare diseases are developed and delivered without delay. We look forward to working with policymakers to advance legislation to accomplish these goals.

Read the full letter here.